2019
DOI: 10.1111/petr.13423
|View full text |Cite
|
Sign up to set email alerts
|

Low‐dose azacitidine for relapse prevention after allogeneic hematopoietic cell transplantation in children with myeloid malignancies

Abstract: Background The prognosis of children who relapse after allogeneic hematopoietic cell transplant (alloHCT) for myeloid malignancies remains poor. Procedure To describe the safety and feasibility of post‐transplant azacitidine for relapse prevention, we retrospectively reviewed the charts of 18 children undergoing alloHCT for myeloid malignancies. Results There were 15 evaluable patients since three patients did not receive planned azacitidine due to early relapse or TRM. Azacitidine (32 mg/m2/dose for 5 days, i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 9 publications
(5 citation statements)
references
References 27 publications
0
5
0
Order By: Relevance
“…Small retrospective analyses suggest improved outcomes in patients who receive post-HCT hypomethylating agents with or without additional interventions such as donor lymphocyte infusion (DLI). (29)(30)(31) Our center has adopted a strategy of reducing blast burden to < 5% pre-HCT in patients with lower intensity approaches including HMAs, as well as pursuing post-HCT HMA therapy for relapse prevention.…”
Section: Discussionmentioning
confidence: 99%
“…Small retrospective analyses suggest improved outcomes in patients who receive post-HCT hypomethylating agents with or without additional interventions such as donor lymphocyte infusion (DLI). (29)(30)(31) Our center has adopted a strategy of reducing blast burden to < 5% pre-HCT in patients with lower intensity approaches including HMAs, as well as pursuing post-HCT HMA therapy for relapse prevention.…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, there was some heterogeneity in our population, in terms of donor/stem cell sources, GVHD prophylaxis, and age/gender. In addition, the duration of the study period (10 years) was prolonged, with a shift in institutional preferences for donor (eg, umbilical cord blood vs haplo/PTCy), as well as adoption of the practice of employing post‐transplant azacitidine maintenance for relapse prevention toward the end of the study period . While the latter was controlled for in the multivariate analysis, confounding may still be present.…”
Section: Discussionmentioning
confidence: 99%
“…Supportive care with antimicrobial prophylaxis and viral reactivation surveillance was based on institutional standards of care. A subset of patients transplanted after February 2015 received post‐transplant azacitidine maintenance for relapse prevention starting as early as d + 42 for up to nine cycles …”
Section: Methodsmentioning
confidence: 99%
“…26 Unfortunately, this study extension to a phase III randomized controlled trial (RCT), failed to show significant differences for OS and DFS between Aza and control groups (p = .85 and p= .14), respectively. 27 However, pediatric case series [28][29] reported low incidence of relapse with prophylactic low-dose Aza (32 to 36 mg/m 2 ) as maintenance post-HCT. Despite the limitations of small numbers, a potential benefit in disease control of this approach warrants further investigation.…”
Section: Dna Hypomethylating Agents (Hmas) Post-hctmentioning
confidence: 99%